GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2009

WIL Research Snags Midwest BioResearch

  • WIL Research, a global CRO focused on early-stage toxicology and development, has acquired Midwest BioResearch (MBR), a Chicago-based CRO focused on preclinical drug disposition and toxicology services.

    MBR’s background is in immunoanalytical and bioassay techniques, small molecule bioanalysis, and genetic toxicology. WIL believes that this will complement its own offerings, which include chronic, neuro-, inhalation, and intravenous toxicology, developmental and reproductive toxicology, safety pharmacology, bioanalytical chemistry, and metabolism.

    “Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities,” says Christopher P. Chengelis, Ph.D., vp and CSO at WIL Research.

    With the addition of MBR, WIL Research Holding now comprises five companies with approximately 1,100 employees in the U.S., Europe, and Japan.

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?